Glaucoma is characterized by a progressive loss of retinal ganglion cells that is often associated with increased intraocular pressure1 and decreased retinal blood flow.2-4 Several pathologic mechanisms may contribute to glaucomatous damage of retinal ganglion cells, including high extracellular concentrations of glutamate,5-7 ischemia,2-4 and lack of growth factors.8,9 As laboratory animals, inbred DBA mice have been used in thousands of studies of immune responses, drug metabolism, epilepsy, and other processes. In previous studies10,11 of the DBA/2J strain of mice, ocular damage associated with mutations in melanosomal proteins that lead to iridocorneal angle closure and increased intraocular pressure has been identified. These changes suggest that these mice may be useful as a model for pigment-related glaucoma that may develop in several breeds of dog12 and perhaps for primary glaucoma in dogs that is often classified as angle-closure or narrow-angle glaucoma.13,14
Taken together, the results of several types of studies5-7,15-17 support the concept that high extracellular concentration of glutamate contributes to glaucomatous cell death. It is well established that high extracellular concentrations of glutamate are toxic to retinal neurons15,16; increases in glutamate concentration in the vitreous body have been reported in primates with primary open-angle glaucoma,7 dogs with primary glaucoma,5 quail with hereditary angle-closure glaucoma,6 and AKXD-28/Ty mice with hereditary pigmentary glaucoma.17 The NMDA antagonist memantine has been shown to decrease ganglion cell death in DBA/2J mice18 and primates,19-21 indicating that activation of glutamate receptors contributes to cell death. Factors that may lead to high extracellular concentration of glutamate associated with some types of glaucoma have also been reported, including decreased blood flow2-4 (which may increase the release of glutamate22,23) and decreased expression of glutamate transporters24,25 (which may lead to decreased uptake of glutamate into cells).
Glaucoma is characterized by visual field defects26 that may be the result of nonuniform loss of ganglion cells and their axons. We hypothesized that such regional damage may be associated with selective release and redistribution of glutamate in the retinal regions with the most severe damage. Recently, our group reported27 focal ischemialike changes in the distribution of glutamate in retinas of dogs with primary glaucoma, compared with findings in dogs with unaffected eyes. These changes included loss of glutamate from neuronal cell bodies and dendrites and an accumulation of glutamate in Müller cells. Changes in glutamate concentration were greatest in damaged regions of the retina, which was consistent with increased glutamate release and excitotoxicosis within these damaged regions. However, primary glaucoma in dogs results in loss of cells from all neuroretinal layers within days of clinical onset.27,28 In our previous study, a substantial depletion of ganglion cells had already occurred in the retinas of dogs with primary glaucoma by the time the disease was diagnosed and samples were obtained. This prevented us from determining whether glutamate was lost from damaged ganglion cells during the early stages of the disease. The acute mechanisms of pathogenesis of glaucoma in dogs may not resemble those seen in other species or types of glaucoma that may take years to reach their end stage. Therefore, we undertook studies of early ganglion cell death in DBA/2J mice. DBA/2J mice have 2 genetic defects10,11 that affect melanosomal proteins. These mutations cause the mice to develop anterior segment defects by 6 months of age.29,30 These changes, including pigment dispersion and anterior and posterior synechia, lead to angle closure and significantly increased intraocular pressure in most mice by 6 to 9 months of age.29,31 The loss of ganglion cells at 9 months of age in DBA/2J mice may be decreased by the glutamate antagonist memantine.18 However, in a recent study,30 it was determined that some ganglion cells of DBA/2J mice may die as early as 3 months of age through an apoptotic mechanism, before increases in intraocular pressure are detected. The purpose of the study reported here was to determine whether glutamate loss occurs from the ganglion cell layer of young DBA/2J mice with glaucoma. The intent was to examine whether the ischemialike losses of neuronal glutamate detected in damaged retinas of dogs with primary glaucoma also occur in DBA/2J mice (which are used as a laboratory animal model of pigmentary glaucoma).
Materials and Methods
All mice used in the study were treated in compliance with the Association for Research in Vision and Ophthalmology Statement for the Use of Animals in Ophthalmic and Vision Research and the Colorado State University Animal Care and Use Committee. The DBA/2J mice,a control CD-1 (ICR) nonpigmented mice,b and control C57/BL6J (pigmented) micea used in the study were housed at the laboratory animal facility of Colorado State University; they were maintained on an alternating cycle of 12 hours of light and 12 hours of dark and fed a standard mouse chow.
Twenty eyes from DBA/2J mice 9 weeks (n = 8) and 4 (4), 6 (4), and 12 months of age (4) and 17 eyes from control CD-1 (7) and C57/BL6J (10) mice ofsimilar age were used. Both eyes of each mouse were utilized. Mice were anesthetized with halothane in a closed chamber and euthanatized by opening the thoracic cavity to air as a simple and effective means of inducing death. Eyes were rapidly dissected from the head of each mouse, and retinas were rapidly fixed with 4% paraformaldehyde and 0.3% glutaraldehyde in 100mM phosphate buffer. Corneas were first punctured with a pointed scalpel blade, and the anterior segment was flushed with fixative by use of a 27gauge needle.32 After 5 minutes, the eyes were hemisected along the ora serrata and the cornea, lens, and vitreous body were removed.30 Eyecups were quartered and immersion fixed for approximately 16 hours; quarters were then processed and embedded in epoxy resin, as previously described.33
Serial 0.5-μm sections were obtained from each eyecup quarter. Sections were stained with toluidine blue (for detection of morphologic signs of damage) or with an immunogold solution (to determine the distribution of glutamate and GFAP). The silver-intensified immunogold technique used was essentially the method that Perlman et al32 used to localize amino acids in ischemic retinas obtained from rats. Sections were etched in sodium ethoxide diluted 1:5 in ethanol for 20 minutes and rinsed in ethanol and then in water. Sections were blocked with 5% goat serum in PBS solution (pH, 7.4; 0.05M phosphate) for 15 minutes and rinsed in PBS solution. Sections were then incubated in rabbit primary antisera against glutamatec that was diluted 1:4,000 or in GFAPd that was diluted 1:100 in PBS solution. Sections were rinsed in PBS solution and incubated for 4 hours at 23°C in ultrasmall gold-labeled secondary antibodiese that were diluted 1:40 in PBS solution containing 1% bovine serum albumin. After rinsing in PBS solution for 45 minutes followed by final brief rinses in distilled water, silver intensification was performed for 6 minutes by use of freshly prepared solution (8.4mM silver nitrate, 0.05mM hydroquinone, and 0.15M citrate buffer [pH, 4.85]). In absorption control specimens (in which the antibodies were preincubated with glutamate conjugated to bovine serum albumin), there was almost no staining of sections (data not shown).
Image capture and analysis—Only retinal regions free from the trauma of dissection and quartering were used for analysis of glutamate distribution. Retinal regions that were distorted because of folding or were near the edges of scissor cuts were associated with a decrease of staining for glutamate in all layers of the retina, compared with retinal regions without these artifacts; regions that had homogeneous loss of staining for glutamate were excluded from the study.
Digital images (130 × 100 μm) were captured by use of a microscopef with special software.g For quantification of the staining density, images were analyzed with image-analysis softwareh by use of methods similar to those previously reported.33,34 Immunostaining densities were measured after inversion accomplished by use of the software’s inversion function. For measurements of immunostaining density, the background staining density of regions of blank plastic was subtracted from retinal staining levels.
To determine the proportion of cells of the ganglion cell layer with high amounts of glutamate, the number of cells with a high density of immunostaining for glutamate in a region was compared with the total number of cells with visible nuclei that were at least 4 μm in diameter in that region of the ganglion cell layer. Cell numbers were determined on a neighboring section stained with toluidine blue. A cell was considered to have a high density of staining for glutamate if more than half of its profile had a staining density >90 (gray scale), as determined by use of the software’s threshold function.
To determine whether glutamate immunostaining was reproducible, repeat measurements of the same region were performed. Six 50 × 100-μm regions of the INL of retinas from DBA/2J mice (from 6 quarters from 3 eyes from 3 mice) were classified by an observer as having homogenously high-, medium-, and low-density staining for glutamate. Immunostaining of serial sections of these regions was repeated the next day. The density of glutamate staining (gray scale) of each region was compared with the density of staining obtained the following day.
Statistical analysis—Data were analyzed to detect significant differences by use of t tests. Statistical softwarewas used for the calculations. Variability was expressed as the SEM unless otherwise specified. A value of P < 0.05 was considered significant.
Results
Assessment of the ganglion cell layer of control and DBA/2J mice—Morphologic signs of damage were observed microscopically in cells of the ganglion cell layers of eyes obtained from DBA/2J mice. In 9-week-old DBA/2J mice, the retinal sections stained with toluidine blue contained cells with darkly stained, irregularly shaped nuclei and dark cytoplasm that was frequently foamy in appearance (Figure 1). In control ICR (age, 9 weeks) and C57/BL6J (age, 8 weeks) mice, similar darkly stained cells were observed rarely (less than or equal to one quarter of each retina). In sections of 27 eyecup quarters from four 9-week-old DBA/2J mice, each contained at least 1 damaged cell and 8 regions with multiple damaged cells in < 100 μm of retinal length that were identified as damaged and used for additional studies. In control ICR mice, no regions with multiple damaged cells were found in 9 eyecup quarters from 6 eyes of three 9-week-old mice or 7 eyecup quarters from 2 eyes of a 4-month-old mouse. In control C57/BL6J mice, 1 of 11 eyecup quarters from 4 eyes of two 8-week-old mice had a region with 3 damaged cells. Other signs of retinal damage observed in 9-week-old DBA/2J mice included lightly stained, swollen structures in the nerve fiber layer that were consistent with degenerating axons. Definitive identification of these structures would require electron microscopic examination in future studies.
Six-and 12-month-old DBA/2J mice also had ganglion cell layer cells with similar signs of damage, but such cells were detected less frequently than they were in retinal specimens from 9-week-old mice (Figure 2). Compared with findings in sections from eyecups obtained from the younger mice, a greater number of swollen cells and processes appeared to be present in the ganglion cell layer and INL of retinas of the older DBA/2J mice, but these differences were not quantified. By 6 months of age and continuing through 12 months of age, immunostaining for GFAP was increased in DBA/2J mice, compared with that detected in both C57/BL6J and ICR control mice, which suggested that reactive glia may be present in retinas of those DBA/2J mice.
Assessment of glutamate immunostaining density in ganglion cell layer regions of control and DBA/2J mice—The ganglion cell layer of retinas obtained from control ICR mice contained a high proportion of cells with dense immunogold staining for glutamate (Figure 3). The mean ± SEM staining density of Müller cell bodies of the INL was low (57 ± 6.6 [gray scale]) in sections from 6 eyecup quarters from four 9-week-old ICR mice. The staining density of most cells of the ganglion cell layer in ICR mice ranged from 100 to 180 (gray scale), which was consistent with the different types of ganglion cells and displaced amacrine cells observed in the ganglion cell layer of these control mice. In 83 ± 8.3% of the cells of the ganglion cell layer in sections from 6 eyecup quarters from four 9-week-old ICR mice, the staining density was ≥ 90 (gray scale). The proportion of cells with high glutamate immunoreactivity ranged from 50% to 100% in the regions quantified. However, in some regions of retinas from 9-week-old control ICR mice and 9-week-old DBA/2J mice, glutamate immunoreactivity was decreased throughout all layers of the retina, compared with undamaged regions. Often, these retinal regions with low glutamate immunoreactivity were near obvious folds or cut edges of the specimen, which led us to speculate that these areas of uniform loss of glutamate immunoreactivity were artifacts resulting from dissection. To exclude these regions of presumptive artifact from the study, all regions of retinas from control and DBA/2J mice that were used for data collection had cells with high levels of glutamate immunoreactivity in the INL (Table 1).
Minimal and maximal densities (± SEM) of immunogold staining of glutamate in cells of the INL and ganglion cell layer in 6 damaged and 6 neighboring undamaged regions of the retinas from 6 eyes of 3 DBA/2J mice. Cells with the highest and lowest levels of glutamate immunoreactivity were selected for measurement in each region.
Location | Cell classification | Staining density* | |
---|---|---|---|
Damaged retinal regions | Undamaged retinal regions | ||
INL | Heavily stained | 129 ± 6.0 | 128 ± 6.3 |
Lightly stained | 40 ± 5.1 | 32 ± 3.0 | |
Ganglion cell layer | Heavily stained | 119 ± 6.6† | 144 ± 5.8 |
Lightly stained | 20 ± 3.7† | 56 ± 6.5 |
Staining density (gray scale) of cells after background staining (assessed by use of blank plastic) was subtracted. Values were determined from a minimum of 17 cells in 6 sections, except for lightly stained ganglion cell layer cells in undamaged areas for which only 6 cells with low-density staining were measured.
Value significantly (P < 0.01) different from that of similarly stained cells in undamaged retinal regions.
The control ICR mice are nonpigmented mice that are not likely to develop problems with pigment dispersion, such as those associated with DBA/2J mice. In addition, densities of immunogold staining for glutamate were measured in a pigmented strain of mice (C57/BL6J) that is commonly used as a control group. Control C57/BL6J mice also had a high proportion of cells with dense immunogold staining for glutamate (94 ± 2.4%) in 8 regions of 8 quarters of 4 eyes from 2 mice.
To minimize the effect of staining variation, the glutamate distribution in damaged and nearby less-damaged retinal regions of DBA/2J mice was examined in the same sections. In 9-week-old DBA/2J mice, undamaged regions of the ganglion cell layer that had a large proportion of cells with high glutamate staining density were identified (Figure 3). The percentage of cells in these regions with high densities of glutamate immunostaining (82 ± 4.2%) was not significantly (P > 0.6) different from the percentage of ganglion cell layer cells with high densities of glutamate immunostaining in 9-week-old control ICR mice (83 ± 8.3%). However, in 8 regions (from 8 quarters of 6 eyes) that had a high frequency of damaged cells in DBA/2J mice, the proportion of ganglion cell layer cells with high densities of glutamate immunostaining was significantly (P < 0.01) decreased to 13 ± 3.2%. Almost all of the cells with morphologic signs of damage had low amounts of glutamate, and many of the neighboring cells that had no obvious signs of damage also had low densities of immunostaining for glutamate (Figure 4).
To determine whether staining artifact could account for the differences in staining for glutamate in the ganglion cell layer of damaged retinal regions, 2 assessments were performed. First, measurements of the reproducibility of density measurements in sections stained on different days were made. Glutamate staining density was highly reproducible in serial sections stained on successive days (Figure 5). Six 50 × 100-μm regions of the INL of retinas from DBA/2J mice (from 6 quarters of 3 eyes from 3 mice) were classified as having homogenously high-, medium-, and low-density staining for glutamate. Immunostaining of serial sections of these regions was repeated the next day. The density of glutamate staining (gray scale) of each region was compared with the density of staining obtained the following day. The mean staining density was highly correlated (R = 0.91), indicating that staining densities were similar when repeated. Secondly, measurements of maximal and minimal staining densities of INL cells in the damaged and undamaged retinal regions were performed. No significant difference in the staining density of heavily labeled cells of the INL in damaged and less-damaged regions was detected, indicating that all immunostaining reagents had access to the INL of damaged retinal regions in sections (Table 1). Similarly, no significant difference in the staining density of the minimally labeled INL cells in the damaged and less-damaged regions was detected. However, despite the similarities of maximal and minimal staining densities of INL cells in damaged and less damaged regions, the percentages of cells with high-and low-density staining often appeared quite different, but further studies would be required to quantify those differences in the INL. In contrast to findings in the INL, the most heavily stained cells and the least heavily stained cells in damaged regions of the ganglion cell layer had significantly lower staining densities than the corresponding cells in undamaged regions of the ganglion cell layer, which was consistent with glutamate depletion in many cell types in the damaged regions.
To determine whether selective loss of cells that contained high concentrations of glutamate could account for glutamate depletion in damaged regions of the ganglion cell layer, the number of cells per millimeter of retina was counted in the damaged regions and in nearby apparently undamaged regions of the retina in 9-week-old DBA/2J mice. In damaged regions, there were 116 ± 13 ganglion cell layer cells/mm of retina, and in undamaged regions, there were 129 ± 6 ganglion cell layer cells/mm of retina. This small difference in the number of cells between damaged and undamaged retinal regions was neither significant (P > 0.4) nor sufficient to account for the greatly decreased number of cells with high glutamate immunoreactivity in damaged regions of retinas in 9-week-old DBA/2J mice. In DBA/2J mice that were 12 months of age, there were 47 ± 3.4 ganglion cell layer cells/mm of retina in regions with low glutamate immunoreactivity; this value was significantly (P < 0.01) less than the value in 9-week-old DBA/2J mice. This decrease in overall cell number in the older mice suggests that large numbers of cells died after 9 weeks of age.
Discussion
Glaucoma is characterized by a nonhomogeneous loss of retinal ganglion cells that results in visual field defects.26 In DBA/2J mice with glaucoma, neuronal death is decreased by the NMDA antagonist, meman-tine,18 which suggests that extracellular glutamate may contribute to retinal damage. We hypothesized that selective release of glutamate in damaged retinal regions may mediate cell death. In rats, glutamate release as a result of ischemia35,36 and other metabolic insults, such as hypoxia37 and hypoglycemia,38 has been detected immunohistochemically and involves a characteristic loss of glutamate from neuronal cell bodies and dendrites. Retinal damage in dogs with primary glaucoma is greater in regions where glutamate immunostaining is decreased in neurons27,33 than in regions with normal glutamate immunostaining, suggesting that there is increased glutamate release in these regions. In the dogs of those studies, it was not possible to perform time-course assessments of neuronal damage and glutamate loss. Primary glaucoma in dogs is frequently classified as narrow-angle or angle-closure glaucoma.13,14 In the present study, we examined the relationship between neuronal damage and glutamate loss in young DBA/2J mice, a strain of mouse that is used to investigate angle-closure glaucoma.
Damaged neurons were observed in the ganglion cell layer of DBA/2J mice at 9 weeks of age and older. Via light microscopy, these damaged cells appeared to have undergone an apoptotic type of cell death similar to that identified via electron microscopy by Schuettauf et al30 in DBA/2J mice at 3 months of age. In our study, the pathologic changes of neurons in 9-week-old DBA/2J mice included homogeneous dark staining of nuclei, irregular nuclear shapes, and dark cytoplasm interspersed with vacuoles. Swollen cell bodies and swelling of the inner plexiform layer (which is characteristic of complete ischemia in rat retinas32,39,40) were not observed in the DBA/2J mice at 9 weeks of age, but they were detected in older mice (at an age at which necrotic types of cell death predominate in retinas of DBA/2J mice30). The DBA/2J mice that were 12 months old also had increased immunostaining for GFAP, a marker for reactive glia. Increased amounts of GFAP in Müller cells are consistent with increased numbers of intermediate filaments that have been identified in Müller cells of 6- to 8-month-old DBA/2J mice.30 Increased amounts of GFAP have also been reported in rats following retinal ischemia that was induced by high intraocular pressure.41,42
In some regions of the retinas obtained from DBA/2J mice, glutamate immunoreactivity was reduced, compared with undamaged regions or control mice. To our knowledge, there are no data to suggest that there are large regional differences in the percentage of cells in the ganglion cell layer that contain high amounts of glutamate in clinically normal vertebrate retinas.32,34 In the retinal sections examined in the present study, 2 types of regional variation were detected. The first type of regional variation was a uniform loss of glutamate immunoreactivity from all layers of the retina in the control ICR and C57/BL6J mice and in the DBA/2J mice. This loss of glutamate immunoreactivity seemed to be associated with retinal defects induced by dissection and was considered an artifact. Retinal regions with uniform glutamate depletion were therefore excluded from the assessments of staining density. The second type of regional variation in glutamate immunoreactivity was detected in damaged regions of the ganglion cell layer of DBA/2J mice; this pathologic loss of glutamate immunoreactivity was distinguished from artifact because glutamate immunoreactivity in the associated INL and other layers was unaffected.
Glutamate immunoreactivity was decreased in damaged regions of ganglion cell layer in the retinas of DBA/2J mice. In some morphologically undamaged retinal regions from 9-week-old DBA/2J mice, glutamate immunoreactivity was high in most cells of the ganglion cell layer and the distribution of glutamate was similar to that detected in clinically normal rodents and other species.32,34,40 Most cells of the ganglion cell layer in many undamaged regions had high densities of immunostaining for glutamate. However, in regions with clusters of damaged cells, far fewer ganglion cell layer cells with high density of immunostaining for glutamate were found. Compared with control mice, immunostaining for glutamate was decreased in neuronal cell bodies and also in structures that might have been degenerating axons in the nerve fiber layer. Essentially all of the damaged cells and a large proportion of the nearby apparently undamaged cells had low densities of immunostaining for glutamate.
Mechanisms other than release of glutamate may contribute to the neuronal glutamate loss detected in damaged regions of retinas obtained from DBA/2J mice. The decreased amounts of intracellular glutamate suggested by the low-density staining for glutamate in damaged retinal regions may also be the result of altered uptake or metabolism of glutamate. In rats, the expression of glutamate transporters may be altered in association with glaucoma,24,25 perhaps contributing to changes in intracellular glutamate concentrations. Altered glutamate metabolism is also suggested by increased amounts of glutamine (a precursor of glutamate) that have been detected in Müller cells in monkeys with glaucoma.43 It has been suggested that these changes in glutamine may reflect an increased glutamate release during development of glaucoma.43
Of interest is the relationship of glutamate redistribution to the pathogenesis of glaucoma. Compared with undamaged regions of DBA/2J retinas, glutamate immunoreactivity in neurons of the ganglion cell layer was decreased in damaged regions of retinas that were 9 weeks old (the earliest age at which retinal damage was assessed). The fact that the number of cells in these regions of decreased glutamate immunoreactivity in young mice was the same as the number of cells in the undamaged retinal areas suggests that glutamate depletion develops early in the disease before substantial cell losses occur. Similar losses of glutamate from neurons occur during ischemia and other insults.35-38 These results are consistent with the hypothesis that glutamate is released from damaged and from neighboring, morphologically undamaged neurons of the ganglion cell layer of the retina during development of glaucoma. This may lead to further glutamate recep-tor–mediated damage in these retinal regions and thus progression of the disease.
In addition to providing an indication of pathologic glutamate release, decreased intracellular glutamate concentration may also contribute to neuronal damage or dysfunction. Glutamate is not only a major excitatory transmitter but also is a direct precursor for the synthesis of glutathione and γ-aminobutyric acid. Depletion of intracellular glutamate may alter synaptic transmission through decreased loading of glutamate or its metabolite, γ-aminobutyric acid, into synaptic vesicles. Glutamate depletion may also decrease the synthesis of the antioxidant glutathione in the retina,44 perhaps resulting in increased oxidative stress in these regions. Oxidative stress has been reported to contribute to retinal damage in some types of glaucoma.45,46
Our data confirm the finding that morphologically evident cell damage develops in DBA/2J mice before intraocular pressure increases at 6 months of age29,31 Furthermore, results of the immunohistochemical evaluation of retinal specimens from DBA/2J mice with glaucoma indicated that neuronal glutamate concentration may be decreased selectively in damaged retinal regions. This loss of glutamate from neurons is similar to that identified in damaged retinal regions in dogs with primary glaucoma. However, in DBA/2J mice, the glutamate loss occurs early in the disease, before intraocular pressure is increased. It remains unknown whether similar loss of glutamate and damage to neurons precede the clinical onset of disease in dogs with primary glaucoma. Depletion of neuronal glutamate in damaged regions is consistent with pathologic release of glutamate in these regions and supports the concept that memantine and other glutamate antagonists may be effective in preventing ganglion cell death in this animal model of angle-closure glaucoma.
NMDA | N-methyl-D-aspartate |
GFAP | Glial fibrillary acidic protein |
INL | Inner nuclear layer |
Jackson Laboratories, Bar Harbor, Me.
Charles River, Wilmington, Mass.
Rabbit anti-glutamate, Sigma Chemical Co, St Louis, Mo.
Glial fibrillary acidic protein, DakoCytomation, Carpinteria, Calif.
Aurion, Electron Microscopy Sciences, Washington, Pa.
Zeis Axioplan 2, Carl Zeiss Microimaging Inc, Thornwood, NY.
Axiovision, version 3.1, Carl Zeiss Microimaging Inc, Thornwood, NY.
ImageJ, version 1.28, National Institutes of Health, Bethesda, Md.
StatWorks, Heyden & Son, Philadelphia, Pa.
- 1↑
Goldberg I. Relationship between intraocular pressure and preservation of visual field in glaucoma. Surv Ophthalmol 2003; 48(suppl 1): S3–S7.
- 2
Birinci H, Danaci M, Oge I, et al.Ocular blood flow in healthy and primary open-angle glaucomatous eyes. Ophthalmologica 2002; 216: 434–437.
- 3
Cheng CY, Liu CJ, Chiou HJ, et al.Color Doppler imaging study of retrobulbar hemodynamics in chronic angle-closure glaucoma. Ophthalmology 2001; 108: 1445–1451.
- 4
Chung HS, Harris A, Evans DW, et al.Vascular aspects in the pathophysiology of glaucomatous optic neuropathy. Surv Ophthalmol 1999; 43(suppl 1): S43–S50.
- 5↑
Brooks DE, Garcia GA, Dreyer EB, et al.Vitreous body glutamate concentration in dogs with glaucoma. Am J Vet Res 1997; 58: 864–867.
- 6↑
Dkhissi O, Chanut E, Wasowicz M, et al.Retinal TUNEL-positive cells and high glutamate levels in vitreous humor of mutant quail with a glaucoma-like disorder. Invest Ophthalmol Vis Sci 1999; 40: 990–995.
- 7↑
Dreyer EB, Zurakowski D, Schumer RA, et al.Elevated glutamate levels in the vitreous body of humans and monkeys with glaucoma. Arch Ophthalmol 1996; 114: 299–305.
- 8
Kerrigan LA, Zack DJ, Quigley HA, et al.TUNEL-positive ganglion cells in human primary open-angle glaucoma. Arch Ophthalmol 1997; 115: 1031–1035.
- 9
Quigley HA, McKinnon SJ, Zack DJ, et al.Retrograde axonal transport of BDNF in retinal ganglion cells is blocked by acute IOP elevation in rats. Invest Ophthalmol Vis Sci 2000; 41: 3460–3466.
- 10
Anderson MG, Smith RS, Hawes NL, et al.Mutations in genes encoding melanosomal proteins cause pigmentary glaucoma in DBA/2J mice. Nat Genet 2002; 30: 81–85.
- 11
Chang B, Smith RS, Hawes NL, et al.Interacting loci cause severe iris atrophy and glaucoma in DBA/2J mice. Nat Genet 1999; 21: 405–409.
- 12↑
van de Sandt R, Boeve MH, Stades FC, et al.Abnormal ocular pigment deposition and glaucoma in the dog. Vet Ophthalmol 2003; 6: 273–278.
- 13
Miller PE. Glaucoma. In: Bonagura JD, Kirk RW, eds. Current veterinary therapy XII. Philadelphia: WB Saunders Co, 1995; 1265–1272.
- 14
Gelatt KN, Brooks D. The canine glaucomas. In: Gelatt KN, ed. Veterinary ophthalmology. 3rd ed. Philadelphia: Lippincott Williams & Wilkins, 1999; 701–754.
- 15
Kwong JM, Lam TT. N-methyl-D-aspartate (NMDA) induced apoptosis in adult rabbit retinas. Exp Eye Res 2000; 71: 437–444.
- 16
Lucas DR, Newhouse JP. The toxic effects of sodium L-glutamate on the inner layers of the retina. Arch Ophthalmol 1957; 58: 193–201.
- 17↑
Anderson MG, Smith RS, Savinova OV, et al.Genetic modification of glaucoma associated phenotypes between AKXD-28/Ty and DBA/2J mice. BMC Genet 2001; 2: 1.
- 18↑
Schuettauf F, Quinto K, Naskar R, et al.Effects of anti-glaucoma medications on ganglion cell survival: the DBA/2J mouse model. Vis Res 2002; 42: 2333–2337.
- 19
Hare W, WoldeMussie E, Lai R, et al.Efficacy and safety of memantine, an NMDA-type open-channel blocker, for reduction of retinal injury associated with experimental glaucoma in rat and monkey. Surv Ophthalmol 2001; 45(suppl 3): S284–S289.
- 20
Hare WA, WoldeMussie E, Lai RK, et al.Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, I: functional measures. Invest Ophthalmol Vis Sci 2004; 45: 2625–2639.
- 21
Hare WA, WoldeMussie E, Weinreb RN, et al.Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, II: structural measures. Invest Ophthalmol Vis Sci 2004; 45: 2640–2651.
- 22
Globus MY, Busto R, Martinez E, et al.Ischemia induces release of glutamate in regions spared from histopathologic damage in the rat. Stroke 1990; 21(suppl 11): III43–III46.
- 23
Meldrum B. Protection against ischaemic neuronal damage by drugs acting on excitatory neurotransmission. Cerebrovasc Brain Metab Rev 1990; 2: 27–57.
- 24
Martin KR, Levkovitch-Verbin H, Valenta D, et al.Retinal glutamate transporter changes in experimental glaucoma and after optic nerve transection in the rat. Invest Ophthalmol Vis Sci 2002; 43: 2236–2243.
- 25
Naskar R, Vorwerk CK, Dreyer EB. Concurrent downregulation of a glutamate transporter and receptor in glaucoma. Invest Ophthalmol Vis Sci 2000; 41: 1940–1944.
- 26↑
Kitazawa Y, Yamamoto T. Glaucomatous visual field defects: their characteristics and how to detect them. Clin Neurosci 1997; 4: 279–283.
- 27↑
McIlnay TR, Gionfriddo JR, Dubielzig RR, et al.Evaluation of glutamate loss from damaged retinal cells of dogs with primary glaucoma. Am J Vet Res 2004; 65: 776–786.
- 28
Whiteman AL, Klauss G, Miller PE, et al.Morphologic features of degeneration and cell death in the neurosensory retina in dogs with primary angle-closure glaucoma. Am J Vet Res 2002; 63: 257–261.
- 29
John SW, Smith RS, Savinova OV, et al.Essential iris atrophy, pigment dispersion, and glaucoma in DBA/2J mice. Invest Ophthalmol Vis Sci 1998; 39: 951–962.
- 30↑
Schuettauf F, Rejdak R, Walski M, et al.Retinal neurode-generation in the DBA/2J mouse—a model for ocular hypertension. Acta Neuropathol (Berl) 2004; 107: 352–358.
- 31
Dyka FM, May CA, Enz R. Metabotropic glutamate receptors are differentially regulated under elevated intraocular pressure. J Neurochem 2004; 90: 190–202.
- 32↑
Perlman JI, McCole SM, Pulluru P, et al.Disturbances in the distribution of neurotransmitters in the rat retina after ischemia. Curr Eye Res 1996; 15: 589–596.
- 33↑
Madl JE, McIlnay TR, Powell CC, et al.Depletion of taurine and glutamate from damaged photoreceptors in the retinas of dogs with primary glaucoma. Am J Vet Res 2005; 66: 791–799.
- 34
Marc RE, Murry RF, Fisher SK, et al.Amino acid signatures in the normal cat retina. Invest Ophthalmol Vis Sci 1998; 39: 1685–1693.
- 35
Torp R, Arvin B, Le Peillet E, et al.Effect of ischaemia and reperfusion on the extra- and intracellular distribution of glutamate, glutamine, aspartate and GABA in the rat hippocampus, with a note on the effect of the sodium channel blocker BW1003C87. Exp Brain Res 1993; 96: 365–376.
- 36
Torp R, Andine P, Hagberg H, et al.Cellular and subcellular redistribution of glutamate-, glutamine- and taurine-like immunoreactivities during forebrain ischemia: a semiquantitative electron microscopic study in rat hippocampus. Neuroscience 1991; 41: 433–447.
- 37↑
Madl JE, Royer SM. Glutamate in synaptic terminals is reduced by lack of glucose but not hypoxia in rat hippocampal slices. Neuroscience 1999; 94: 417–430.
- 38↑
Gundersen V, Fonnum F, Ottersen OP, et al.Redistribution of neuroactive amino acids in hippocampus and striatum during hypoglycemia: a quantitative immunogold study. J Cereb Blood Flow Metab 2001; 21: 41–51.
- 39
Izumi Y, Hammerman SB, Kirby CO, et al.Involvement of glutamate in ischemic neurodegeneration in isolated retina. Vis Neurosci 2003; 20: 97–107.
- 40
Napper GA, Kalloniatis M. Neurochemical changes following postmortem ischemia in the rat retina. Vis Neurosci 1999; 16: 1169–1180.
- 41
Kim IB, Kim KY, Joo CK, et al.Reaction of Muller cells after increased intraocular pressure in the rat retina. Exp Brain Res 1998; 121: 419–424.
- 42
Osborne NN, Larsen AK. Antigens associated with specific retinal cells are affected by ischaemia caused by raised intraocular pressure: effect of glutamate antagonists. Neurochem Int 1996; 29: 263–270.
- 43↑
Carter-Dawson L, Shen F, Harwerth RS, et al.Glutamine immunoreactivity in Muller cells of monkey eyes with experimental glaucoma. Exp Eye Res 1998; 66: 537–545.
- 44↑
Reichelt W, Stabel-Burow J, Pannicke T, et al.The glutathione level of retinal Muller glial cells is dependent on the high-affinity sodium-dependent uptake of glutamate. Neuroscience 1997; 77: 1213–1224.
- 45
Neufeld AH. Nitric oxide: a potential mediator of retinal ganglion cell damage in glaucoma. Surv Ophthalmol 1999; 43(suppl 1): S129–S135.
- 46
Siu AW, Leung MC, To CH, et al.Total retinal nitric oxide production is increased in intraocular pressure-elevated rats. Exp Eye Res 2002; 75: 401–406.